Search clinical trials for: MUC1-KLH vaccine/QS21

Total 67 results

Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating Patients With Ovarian, Fallopian Tube, or Peritoneal Cancer

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cavity Cancer

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating Patients With Breast Cancer

Breast Cancer

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Vaccine Therapy Plus QS21 in Treating Patients With Prostate Cancer

Prostate Cancer

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Vaccine Therapy Plus QS21 in Treating Patients With Progressive Prostate Cancer

Prostate Cancer

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Vaccine Therapy Plus QS21 in Treating Patients With Prostate Cancer

Prostate Cancer

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating Patients at High Risk for Breast Cancer Recurrence

Breast Cancer

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Vaccine Therapy Plus QS21 in Treating Women With Breast Cancer Who Have No Evidence of Disease

Breast Cancer

United States
European Organisation for Research and Treatment...

Unknown

Vaccine Therapy in Treating Patients With Primary Stage II Melanoma

Melanoma (Skin)

Italy, France, Spain, Switzerland, United Kingdom, Belgium, Australia, Norway, Poland, Finland, Netherlands, Germany, Israel, Denmark, Serbia, Estonia, Portugal, Russian Federation
National Cancer Institute (NCI)

Terminated

Vaccine Therapy in Treating Patients With Metastatic Breast Cancer

Male Breast Cancer | Stage IV Breast Cancer | Recurrent Breast Cancer

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Vaccine Therapy Plus Biological Therapy in Treating Patients With Prostate Cancer

Prostate Cancer

United States
National Cancer Institute (NCI)

Active, not recruiting

Vaccine Therapy and Sargramostim in Treating Patients With Pancreas Cancer That Cannot Be Removed By Surgery

Pancreatic Ductal Adenocarcinoma | Stage III Pancreatic Cancer AJCC v6 and v7 | Stage IV Pancreatic Cancer AJCC v6 and v7 | Pancreatic Acinar Cell Carcinoma | Locally Advanced Pancreatic Adenocarcinoma

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Vaccine Therapy Plus QS21 in Treating Patients With Progressive Prostate Cancer

Prostate Cancer

United States
Memorial Sloan Kettering Cancer Center

Completed

Vaccination of Prostate Cancer Patients With MUC-2-KLH Conjugate Plus the Immunological Adjuvant QS21

Prostate Cancer

United States
M.D. Anderson Cancer Center

Terminated

Trial of ID-Specific Donor Vaccinated Lymphocyte Infusion for Patients With Myeloma Relapsing or Failing to Achieve a Complete Remission After an Allogenic Transplant

Myeloma

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating Patients With Chronic Myelogenous Leukemia

Leukemia

United States
National Cancer Institute (NCI)

Completed

Treatment of Castration Resistant Prostate Cancer Using Multi-Targeted Recombinant Ad5 PSA/MUC1/Brachyury Based Immunotherapy Vaccines

Prostatic Neoplasms | Prostatic Cancer

United States
Prima BioMed Ltd

Completed

Ovarian Cancer Vaccine for Patients Who Have Progressed During the CAN-003 Study (CAN-003X)

Epithelial Ovarian Cancer

United States, Australia
Jonsson Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating Patients With Advanced Cancer

Unspecified Adult Solid Tumor, Protocol Specific

United States
Donald T. Weed, MD, FACS

Completed

PDE5 Inhibition Via Tadalafil to Enhance Anti-Tumor Mucin 1 (MUC1) Vaccine Efficacy in Patients With HNSCC

Head and Neck Cancer | Head and Neck Squamous Cell Carcinoma

United States
National Cancer Institute (NCI)

Completed

Multi-Targeted Recombinant Ad5 (CEA/MUC1/Brachyury) Based Immunotherapy Vaccine Regimen in People With Advanced Cancer

Neoplasms | Breast Cancer | Lung Cancer | Prostate Cancer | Colon Cancer

United States
Hoffmann-La Roche

Completed

A Study to Evaluate the Effects of Ocrelizumab on Immune Responses In Participants With Relapsing Forms of Multiple Sclerosis

Multiple Sclerosis, Relapsing-Remitting

Canada, United States
National Cancer Institute (NCI)

Completed

Active Specific Immunotherapy for Follicular Lymphomas With Tumor-Derived Immunoglobulin Idiotype Antigen Vaccines

Lymphoma | Follicular Lymphoma | B Cell Lymphoma

United States
Fox Chase Cancer Center
National Cancer Institute (NCI)

Completed

Vaccine Therapy Plus QS21 in Treating Patients With Advanced Pancreatic or Colorectal Cancer

Colorectal Cancer | Pancreatic Cancer
Leo W. Jenkins Cancer Center
H. Lee Moffitt Cancer Center and Research Institute

Terminated

Direct Tumor Injection KLH-Pulsed Dendritic Cells in Unresectable Pancreatic Cancer

Metastatic Pancreatic Cancer

United States
National Cancer Institute (NCI)

Completed

Therapy to Treat Ewing's Sarcoma, Rhabdomyosarcoma or Neuroblastoma

Sarcoma | Neuroectodermal Tumors, Primitive, Peripheral | Neuroblastoma | Rhabdomyosarcoma-Embryonal | Rhabdomyosarcoma- Alveolar

United States
Masonic Cancer Center, University of Minnesota

Terminated

Vaccination With Tetanus and KLH to Assess Immune Responses.

Cancer

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Immunization With a Pentavalent Vaccine Composed of KLH-conjugates of GD2L, GD3L, Globo H, Fucosyl GM1, and N-Propionylated Polysialic Acid

Lung Cancer

United States
H. Lee Moffitt Cancer Center and Research Institute
Johns Hopkins All Children's Hospital

Withdrawn

A Combined Cell Therapy Approach to the Treatment of Neuroblastoma

Neoplasms, Nerve Tissue | Neuroblastoma
National Institute of Allergy and Infectious Diseases...
Atopic Dermatitis and Vaccinia Network

Completed

Responses to Immunization With Keyhole Limpet Hemocyanin Administered by Scarification and the Intradermal Route

Atopic Dermatitis

United States
Karen Kelly
Bristol-Myers Squibb; National Cancer Institute (NCI); Transgene

Completed

TG4010 and Nivolumab in Patients With Lung Cancer

Stage IIIA Non-Small Cell Lung Cancer | Stage IIIB Non-Small Cell Lung Cancer | Recurrent Non-Small Cell Lung Carcinoma | Stage IV Non-Small Cell Lung Cancer | Stage I Non-Small Cell Lung Cancer | Stage II Non-Small Cell Lung Cancer

United States
National Cancer Institute (NCI)

Recruiting

Testing a Combination of Vaccines for Cancer Prevention in Lynch Syndrome

Lynch Syndrome

United States, Puerto Rico
John Sampson
National Cancer Institute (NCI)

Completed

Chemotherapy, Radiation Therapy, and Vaccine Therapy With Basiliximab in Treating Patients With Glioblastoma Multiforme That Has Been Removed by Surgery (ZAP IT)

Malignant Neoplasms of Brain

United States
National Cancer Institute (NCI)

Recruiting

Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Cancer (mCRC)

Metastatic Colorectal Cancer

United States
Fred Hutchinson Cancer Research Center/University...
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating Patients With Multiple Myeloma Who Have Undergone Stem Cell Transplantation

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple Myeloma

United States
Hadassah Medical Organization
Vaxil Therapeutics Ltd.

Withdrawn

A Novel Vaccine for the Treatment of MUC1-expressing Tumor Malignancies

Multiple Myeloma | Tumors

Israel
Novartis Pharmaceuticals

Recruiting

Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS (ALITHIOS)

Relapsing Multiple Sclerosis

United States, Australia, Austria, Belgium, Bulgaria, Canada, Germany, Hungary, Poland, Portugal, Russian Federation, Slovakia, Spain, Denmark, France, Japan, Israel, Taiwan, Turkey, Czechia, Argentina, Estonia, United Kingdom, India, C... and more
University of Virginia
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating Patients With Metastatic Melanoma

Melanoma (Skin)

United States
Memorial Sloan Kettering Cancer Center
Y-mAbs Therapeutics

Active, not recruiting

Bivalent Vaccine With Escalating Doses of the Immunological Adjuvant OPT-821, in Combination With Oral β-glucan for High-Risk Neuroblastoma

Neuroblastoma

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Withdrawn

Vaccine Therapy and OPT-821 or OPT-821 Alone in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer in Complete Remission

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cavity Cancer
University of York
Wellcome Trust; European and Developing Countries Clinical Trials Partnership... and other collaborators

Withdrawn

A Study to Assess Safety and Efficacy of a Leishmania Vaccine to Prevent Post Kala Azar Dermal Leishmaniasis (PKDL) (LEISH3)

Post-kala-azar Dermal Leishmaniasis
Mayo Clinic
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating Patients With Previously Treated Stage II or Stage III Breast Cancer

Breast Cancer

United States
National Cancer Institute (NCI)

Completed

Vaccination of Follicular Lymphomas With Tumor-Derived Immunoglobulin Idiotype

Follicular Lymphoma | B Cell Lymphoma | Neoplasm

United States
Maria Sklodowska-Curie National Research Institute...

Unknown

Melanoma Vaccine in Treating Patients With Stage III Melanoma After Surgery to Remove Lymph Nodes

Melanoma (Skin)

Poland
Genitope Corporation

Terminated

Personalized Active Immunotherapy (Vaccine Therapy) and Sargramostim Given After Standard of Care Treatment With Rituximab and Chemotherapy for Initial Treatment With Lymphoma

Non-Hodgkin's Lymphoma

United States
National Cancer Institute (NCI)

Active, not recruiting

MUC1 Vaccine in Preventing Lung Cancer in Current and Former Smokers at High Risk for Lung Cancer

Lung Carcinoma

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Vaccine Therapy and QS21 in Treating Patients With Metastatic Breast Cancer

Breast Cancer

United States
National Cancer Institute (NCI)

Completed

Active Immunization of Sibling Bone Marrow Transplant Donors Against Purified Myeloma Protein of the Recipient Undergoing Allogeneic Bone Marrow Transplantation

Multiple Myeloma | Graft vs Host Disease

United States
Joseph Baar, MD, PhD

Completed

MUC1 Vaccine for Triple-negative Breast Cancer

Breast Cancer | Stage I Breast Cancer | Inflammatory Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIIC Breast Cancer

United States
Genitope Corporation

Completed

Vaccine Therapy and Sargramostim After Rituximab in Treating Patients With Refractory or Progressive Non-Hodgkin's Lymphoma

Lymphoma

United States, Canada
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

OPT-821 With or Without Vaccine Therapy in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in Second or Third Complete Remission

Stage IIA Fallopian Tube Cancer | Stage IIA Ovarian Cancer | Stage IIB Fallopian Tube Cancer | Stage IIB Ovarian Cancer | Stage IIC Fallopian Tube Cancer | Stage IIC Ovarian Cancer | Stage IIIA Fallopian Tube Cancer | Stage IIIA Ovarian Cancer | Stage IIIA Primary Peritoneal Cancer | Stage IIIB Fallopian... and other conditions

United States

Search clinical trials for: MUC1-KLH vaccine/QS21

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Montenegro

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations